BioCentury
ARTICLE | Clinical News

Kyowa's XLH candidate Crysvita gets nod from EMA's CHMP

December 22, 2017 12:13 AM UTC

EMA's CHMP recommended conditional approval of Crysvita burosumab (KRN23, UX023) from Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) to treat X-linked hypophosphatemia (XLH) with radiographic evidence of bone disease in children ages one and up and adolescents with growing skeletons...